309 related articles for article (PubMed ID: 21194571)
1. Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical.
Heath BM; Cui Y; Worton S; Lawton B; Ward G; Ballini E; Doe CP; Ellis C; Patel BA; McMahon NC
J Pharmacol Toxicol Methods; 2011; 63(3):258-68. PubMed ID: 21194571
[TBL] [Abstract][Full Text] [Related]
2. Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment.
Cros C; Skinner M; Moors J; Lainee P; Valentin JP
Toxicol Appl Pharmacol; 2012 Dec; 265(2):200-8. PubMed ID: 23073507
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs.
Sällström J; Al-Saffar A; Pehrson R
J Pharmacol Toxicol Methods; 2014; 69(1):24-9. PubMed ID: 24140388
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome.
Shimizu W; Antzelevitch C; Suyama K; Kurita T; Taguchi A; Aihara N; Takaki H; Sunagawa K; Kamakura S
J Cardiovasc Electrophysiol; 2000 Dec; 11(12):1320-9. PubMed ID: 11196553
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms underlying increased right ventricular conduction sensitivity to flecainide challenge.
Veeraraghavan R; Poelzing S
Cardiovasc Res; 2008 Mar; 77(4):749-56. PubMed ID: 18056761
[TBL] [Abstract][Full Text] [Related]
6. Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp.
Penniman JR; Kim DC; Salata JJ; Imredy JP
J Pharmacol Toxicol Methods; 2010; 62(2):107-18. PubMed ID: 20601018
[TBL] [Abstract][Full Text] [Related]
7. Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
Osadchii OE
J Cardiovasc Pharmacol; 2014 Mar; 63(3):240-51. PubMed ID: 24220314
[TBL] [Abstract][Full Text] [Related]
8. An examination of the cardiac actions of PD117,302, a κ-opioid receptor agonist.
Pugsley MK; Saint DA; Hayes ES; Abraham S; Walker MJ
Eur J Pharmacol; 2015 Aug; 761():330-40. PubMed ID: 26086860
[TBL] [Abstract][Full Text] [Related]
9. Electrocardiographic interactions between pinacidil, a potassium channel opener and class I antiarrhythmic agents in guinea-pig isolated perfused heart.
Yang Q; Padrini R; Bova S; Piovan D; Magnolfi G
Br J Pharmacol; 1995 Apr; 114(8):1745-9. PubMed ID: 7599944
[TBL] [Abstract][Full Text] [Related]
10. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.
Desaphy JF; De Luca A; Didonna MP; George AL; Camerino Conte D
J Physiol; 2004 Jan; 554(Pt 2):321-34. PubMed ID: 14608015
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide.
Desaphy JF; Dipalma A; Costanza T; Bruno C; Lentini G; Franchini C; George A; Conte Camerino D
Br J Pharmacol; 2010 Jul; 160(6):1521-33. PubMed ID: 20590641
[TBL] [Abstract][Full Text] [Related]
12. Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.
Ingleby-Talecki L; van Dijkman SC; Oosterholt SP; Della Pasqua O; Winter C; Cunnington M; Rebar L; Forero-Schwanhaeuser S; Patel V; Cooper JA; Bahinski A; Chaudhary KW
Clin Transl Sci; 2022 Aug; 15(8):1978-1989. PubMed ID: 35579204
[TBL] [Abstract][Full Text] [Related]
13. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
Lu HR; Rohrbacher J; Vlaminckx E; Van Ammel K; Yan GX; Gallacher DJ
Br J Pharmacol; 2010 May; 160(1):60-76. PubMed ID: 20331615
[TBL] [Abstract][Full Text] [Related]
14. Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation.
Aoike F; Takahashi MP; Sakoda S
Eur J Pharmacol; 2006 Feb; 532(1-2):24-31. PubMed ID: 16473348
[TBL] [Abstract][Full Text] [Related]
15. Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks.
Harmer AR; Abi-Gerges N; Easter A; Woods A; Lawrence CL; Small BG; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2008; 57(1):30-41. PubMed ID: 17980627
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activation of IKr impairs conduction in guinea pig hearts.
Larsen AP; Olesen SP; Grunnet M; Poelzing S
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):923-9. PubMed ID: 20163495
[TBL] [Abstract][Full Text] [Related]
17. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
18. Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.
Ranger S; Talajic M; Lemery R; Roy D; Nattel S
Circulation; 1989 May; 79(5):1000-6. PubMed ID: 2540920
[TBL] [Abstract][Full Text] [Related]
19. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
[TBL] [Abstract][Full Text] [Related]
20. Combined application of class I antiarrhythmic drugs causes "additive", "reductive", or "synergistic" sodium channel block in cardiac muscles.
Kawamura T; Kodama I; Toyama J; Hayashi H; Saito H; Yamada K
Cardiovasc Res; 1990 Nov; 24(11):925-31. PubMed ID: 2176934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
